10-QPeriod: Q3 FY2012

ABBOTT LABORATORIES Quarterly Report for Q3 Ended Sep 30, 2012

Filed November 7, 2012For Securities:ABT

Summary

Abbott Laboratories reported solid financial performance for the nine months ended September 30, 2012, with net sales reaching $29.04 billion, an increase from $28.47 billion in the same period last year. Diluted earnings per share were $3.06. The company saw strong performance in its Proprietary Pharmaceutical Products segment, with net sales of $12.87 billion year-to-date. The company is actively managing its business through various initiatives, including restructuring plans aimed at streamlining operations and improving efficiencies. These efforts, along with strategic acquisitions and collaborations in research and development, position Abbott for future growth. Notably, Abbott announced its plan to separate into two publicly traded companies, one focused on diversified medical products and the other on research-based pharmaceuticals, expected by January 1, 2013. This strategic move is intended to unlock greater value for shareholders.

Financial Highlights

54 data points
Beta

Revenue

$5.26B

49.0% Gross Margin

Net Income

$1.94B

36.9% Net Margin

EPS (Diluted)

$1.21

Total Assets

$63.26B

Cash & Equivalents

$8.00B

Free Cash Flow

$2.99B

Financial Statements
Beta
Revenue$5.26B
Cost of Revenue$2.49B
Gross Profit$2.58B
SG&A Expenses$1.92B
Operating Expenses$4.95B
Operating Income$310.02M
Interest Expense$152.03M
Net Income$1.94B
EPS (Basic)$1.22
EPS (Diluted)$1.21
Shares Outstanding (Basic)1.58B
Shares Outstanding (Diluted)1.59B

Key Highlights

  • 1Net sales for the nine months ended September 30, 2012, were $29.04 billion, up from $28.47 billion in the prior year period.
  • 2Diluted earnings per share for the nine months were $3.06, compared to $1.98 in the prior year period.
  • 3The Proprietary Pharmaceutical Products segment showed strong year-to-date sales of $12.87 billion.
  • 4Abbott announced a plan to separate into two independent, publicly traded companies by January 1, 2013.
  • 5Significant cash flow from operations of $7.81 billion was generated during the first nine months of 2012.
  • 6The company recorded $386 million in tax benefits in Q3 2012 due to the favorable resolution of prior tax positions.
  • 7Abbott has entered into various collaborations and made acquisitions to advance its product pipeline, including significant charges for acquired in-process R&D.

Frequently Asked Questions

Abbott Laboratories demonstrates a stable financial position with increased net sales and earnings for the first nine months of 2012 compared to the same period in 2011. The company generated substantial operating cash flow and maintained a healthy working capital position. While facing some challenges like unfavorable foreign exchange rates and restructuring costs, the overall financial performance appears robust.

The most significant strategic initiative is the planned separation of the company into two distinct publicly traded entities: one for diversified medical products and another for research-based pharmaceuticals, expected by January 1, 2013. Additionally, Abbott is actively pursuing business combinations and technology acquisitions to enhance its product pipeline and is implementing restructuring plans to improve operational efficiency.

Yes, Abbott has resolved significant legal matters, including a $1.5 billion charge in Q3 2011 related to a government investigation into Depakote sales and marketing activities, with the remainder of the settlement paid in October 2012. The company also finalized its patent litigation with Centocor regarding Humira. Abbott is subject to ongoing government regulations and has entered into a Corporate Integrity Agreement (CIA) and probation, which carry compliance obligations and potential penalties for non-compliance.

The separation is intended to unlock shareholder value by allowing each new company to focus on its respective core businesses and pursue more tailored growth strategies. Investors will receive shares in the newly formed research-based pharmaceutical company. The historical results of this business will be presented as discontinued operations post-separation.